Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Johnson & Johnson : Announces Quarterly Dividend for Fourth Quarter 2020

10/22/2020 | 02:17pm EST

NEW BRUNSWICK, N.J., Oct. 22, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2020 of $1.01 per share on the company's common stock. The dividend is payable on December 8, 2020 to shareholders of record at the close of business on November 24, 2020. The ex-dividend date is November 23, 2020.

About Johnson & Johnson

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.                  

            

(PRNewsfoto/Johnson & Johnson)

Cision
View original content to download multimedia:http://www.prnewswire.com/news-releases/johnson--johnson-announces-quarterly-dividend-for-fourth-quarter-2020-301158284.html

SOURCE Johnson & Johnson


© PRNewswire 2020
All news about JOHNSON & JOHNSON
12/01JOHNSON & JOHNSON : European Commission Approves Janssen's TREMFYA®▼ (guse..
PU
12/01JOHNSON & JOHNSON : New Survey Finds Critical Need for Education on Cataracts an..
PR
11/27Covid-19 Vaccine Studies May Suffer as Volunteers Consider Dropping Out
DJ
11/26JOHNSON & JOHNSON : Janssen Pharmaceutical Companies - European Commission Appro..
AQ
11/25JOHNSON & JOHNSON : Pfizer, and Merck Lost $3.5B in Combined YTD Revenue
AQ
11/23JOHNSON & JOHNSON : Janssen Submits Paliperidone Palmitate 6-Month (PP6M) Supple..
PU
11/23JOHNSON & JOHNSON : Initiates Second Global Phase 3 Clinical Trial of its Jansse..
PU
11/23JOHNSON & JOHNSON : New XARELTO® (rivaroxaban) Peripheral Artery Disease (PAD) D..
PU
11/23JOHNSON & JOHNSON : Janssen Submits Application to U.S. FDA for New Indication t..
PU
11/23JOHNSON & JOHNSON : Late-Breaking 12-Month Data of Investigational RPGR Gene The..
PU
More news